Recent Blog Articles

Stepping into the Vioxx void

March 09, 2014

(Reviewed/revised April 2005)

Answers to four questions after the popular pain reliever was yanked off the market.

In September 2004, Merck announced that it was pulling rofecoxib (Vioxx) off the market. The decision came after an interim analysis of a colon polyp prevention trial showed that twice as many people taking the drug had a heart attack or stroke as those taking a placebo.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».


As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.